June 20, 2025 Release Highlights Copied
Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Enhancing Oncology Model (EOM).
MIPS Quality Measures Dashboard
The MIPS Quality Measures Dashboard will be updated to reflect the below refinement(s):
| Measure | Description | Practice Impact |
|---|---|---|
| PIMSH 17: Utilization of Prophylactic GCSF for Cancer Patients Receiving Low‑Risk Chemotherapy (Inverse Measure) | This is a new QCDR measure gauging the use of GCSF in patients receiving low-risk chemotherapy.
Denominator includes all patients with cancer (solid tumors only) receiving their first cycle of low-risk chemotherapy within the measurement period with a qualifying encounter during the measurement period. Requires one qualifying encounter during the measurement period. Denominator Exclusion:
Numerator:
|
Establish a numerator and denominator for this new measure.
New measures in their first year of reporting have a 7-point benchmark floor if data completeness of 75% is met. |
| MIPS 144: Pain Care Plan | Denominator Criteria 1:
Denominator Criteria 2:
|
Minimal decrease in denominator and/or numerator count. |
EOM Performance Measures Dashboard
The EOM Performance Measures Dashboard will be updated to reflect the below refinement(s):
| Measure | Description | Practice Impact |
|---|---|---|
| EOM-4A: Pain Intensity Quantified | Denominator Criteria 1:
Denominator Criteria 2:
|
Minimal decrease in denominator and/or numerator count. |
Status of Dashboard Updates for 2025
CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2025 requirements.
| Measure | Description |
|---|---|
| MIPS Quality Measures Dashboard | |
| MIPS #001 | Diabetes Hemoglobin A1c (HbA1cc) Poor Control (>9%) (Inverse Measure) |
| MIPS #047 | Advance Care Plan |
| MIPS #130 | Current Medications Documentation |
| MIPS #143 | Pain Intensity Quantified |
| MIPS #144 | Pain Care Plan |
| MIPS #226 | Tobacco Screening and Cessation |
| MIPS #236 | Controlling High Blood Pressure |
| MIPS #238 | Use of High-Risk Medications in Older Adults (Inverse Measure) |
| MIPS #374 | Closing the Referral Loop |
| MIPS #450 | Appropriate Treatment for Patients with Stage I (T1c) III Her2 Positive Breast Cancer |
| MIPS #451 | RAS (KRAS & NRAS) Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-EGFR Monoclonal Antibody Therapy |
| MIPS #453 | Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure) |
| MIPS #457 | Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days |
| MIPS #462 | Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
| MIPS #487 | Screening for Social Drivers of Health |
| PIMSH #1 | Advance Care Planning in Metastatic Disease |
| PIMSH #9 | Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
| PIMSH #10 | Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs |
| PIMSH #13 | Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy |
| PIMSH #15 | Antiemetic Therapy for Low-and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure) |
| PIMSH #16 | Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center |
| PIMSH #17 | Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure) |
| EOM Performance Measures Dashboard | |
| EOM-4A | Pain Intensity Quantified |